Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) (ACE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00989261 |
|
Recruitment Status :
Completed
First Posted : October 5, 2009
Results First Posted : November 29, 2019
Last Update Posted : December 11, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia | Drug: Compound AC220 | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 333 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 2 Open-Label, AC220 Monotherapy Efficacy (ACE) Study in Patients With Acute Myeloid Leukemia (AML) With and Without FLT3-ITD Activating Mutations |
| Study Start Date : | November 2009 |
| Actual Primary Completion Date : | September 28, 2012 |
| Actual Study Completion Date : | December 31, 2014 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Cohort 1; ≥60 years of age
Participants ≥60 years of age who were relapsed after one first-line chemotherapy regimen (with or without consolidation) and after first complete remission <12 months or are primary refractory to first-line chemotherapy received a starting dose of 200 mg/day quizartinib. Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-) After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day. |
Drug: Compound AC220
Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Other Name: AC010220 × 2HCl, oral powder for reconstitution |
|
Experimental: Cohort 2; ≥18 years of age
Participants ≥18 years of age (including participants ≥60 years of age) who were relapsed or refractory after one second-line (salvage) regimen or after hematopoietic stem cell transplant (HSCT) received a starting dose of 200 mg/day quizartinib. Exploratory: FLT3-ITD (+) and FLT3-ITD (-) Confirmatory: FLT3-ITD (+) and FLT3-ITD (-) After an amendment, male participants received a starting dose of 135 mg/day quizartinib and all females received a starting dose of 90 mg/day. |
Drug: Compound AC220
Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
Other Name: AC010220 × 2HCl, oral powder for reconstitution |
- Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants) [ Time Frame: Within the first 3 cycles of treatment (84 days) ]
Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[+] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia <1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.
- Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [-] Participants) [ Time Frame: Within the first 3 cycles of treatment (84 days) ]
Derived disease assessment based on local morphology of bone marrow disease performed by each local site pathologist, including all on-treatment data (Safety Population, FLT3-ITD[-] Participants)
Modified from Cheson et al, abbreviations include the following: CR=complete remission; CRc=composite complete remission (CR+CRp+CRi); CRi=complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia=all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia <1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib=All criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion; CRp=complete remission with incomplete platelet recovery; NR=no response; PR=partial remission.
- Number of Participants With Composite Complete Remission (CRc), Categorised by FLT3-ITD Status [ Time Frame: within 28 months ]CRc is defined as composite complete remission (CR+CRp+CRi) - CR = complete remission; CRp = complete remission with incomplete platelet recovery; CRi = complete remission with incomplete hematological recovery, includes participants who met CRia criteria plus participants who met CRib criteria; CRia = all criteria specified for CR are met except for incomplete hematological recovery with residual neutropenia <1 x 10^9/L with or without complete platelet recovery. Red blood cell and platelet transfusion independence is not required; CRib = all criteria for CR or CRp are met, except for recent red blood cell or platelet transfusion.
- Duration of Composite Complete Remission in FLT3-ITD (+) Participants Who Achieved CRc Based on All On-Treatment Data [ Time Frame: From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment ]
Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of >1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.
- Duration of Composite Complete Remission in FLT3-ITD (-) Participants Who Achieved CRc Based on All On-Treatment Data [ Time Frame: From time at which CRc was achieved until disease progression or death, up to approximately 3 years post treatment ]
Kaplan-Meier analysis of duration of composite complete remission derived based on local morphology including all on-treatment data (Safety Population).
The definition of relapse at CRc includes an evaluation of blasts in the peripheral blood of >1%.Though not specified in the protocol, the addition of these criteria was deemed necessary for consistency with the Cheson criteria.
- Duration of Any Response in FLT3-ITD (+) Participants [ Time Frame: From the time of any response until disease progression or death, up to approximately 3 years post treatment ]Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).
- Duration of Any Response in FLT3-ITD (-) Participants [ Time Frame: From the time of any response until disease progression or death, up to approximately 3 years post treatment ]Kaplan-Meier analysis of duration of any response (CR, CRp, CRi, or PR), derived based on local morphology for participants who achieved a response during the first 3 cycles of treatment (Safety Population).
- Median Duration of Leukemia-free Survival in FLT3-ITD (+) Participants [ Time Frame: From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment ]Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).
- Median Duration of Leukemia-free Survival in FLT3-ITD (-) Participants [ Time Frame: From the time CRc was achieved until disease progression or death, up to approximately 3 years post treatment ]Kaplan-Meier analysis of leukemia-free survival in participants who achieved a CRc in the first three cycles of treatment derived based on local morphology (Safety Population).
- Median Duration of Overall Survival in FLT3-ITD (+) Participants [ Time Frame: Time from first dose to death from any cause, up to 3 years post treatment ]Kaplan-Meier analysis of overall survival (Safety Population)
- Median Duration of Overall Survival in FLT3-ITD (-) Participants [ Time Frame: Time from first dose to death from any cause, up to approximately 3 years post treatment ]Kaplan-Meier analysis of overall survival (Safety Population)
- Early Treatment-related Death [ Time Frame: Within first 3 cycles of treatment (84 days) ]Early treatment-related deaths included all treatment-related deaths prior to the end of Cycle 3 with a 3-day window (Cycle 3 end date + 3 days), unless the death was following a CRc response assessed by the Investigator.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Current enrollment is open only to FLT3-ITD positive, Cohort 1.
Inclusion Criteria:
- Males and females age ≥18 years in second relapse or refractory.
- Males and females age ≥60 years in first relapse or refractory.
- Must have baseline bone marrow sample taken.
- Morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS with ≥20% bone marrow or peripheral blasts), as defined by the World Health Organization (WHO) criteria, confirmed by pathology review at treating institution.
- Able to swallow the liquid study drug.
- Eastern Cooperative Oncology Group performance status of 0 to 2
- In the absence of rapidly progressing disease, the interval from prior treatment to time of AC220 administration will be at least 2 weeks for cytotoxic agents or at least 5 half-lives for noncytotoxic agents. The use of chemotherapeutic or antileukemic agents other than hydroxyurea is not permitted during the study with the possible exception of intrathecal (IT) therapy at the discretion of the Investigator and with the agreement of the Sponsor.
- Persistent chronic clinically significant non-hematological toxicities from prior treatment must be ≤Grade 1.
- Prior therapy with FLT3 inhibitors is permitted, except previous treatment with AC220.
- Serum creatinine ≤1.5 × upper limit of normal (ULN) and glomerular filtration rate (GFR) > 30 mL/min
- Serum potassium, magnesium, and calcium levels should be at least within institutional normal limits.
- Total serum bilirubin ≤1.5 × ULN
- Serum aspartate transaminase (AST) and/or alanine transaminase (ALT) ≤2.5 × ULN
- Females of childbearing potential must have a negative pregnancy test (urine β-hCG).
- Females of childbearing potential and sexually mature males must agree to use a medically accepted method of contraception throughout the study.
- Written informed consent must be provided.
Exclusion Criteria:
- Patients over the age of 85 years except at the discretion of the Investigator and with agreement of the Sponsor.
- Diagnosis of acute promyelocytic leukemia
- Diagnosis of chronic myelogenous leukemia (CML) in blast crisis
- AML in relapse or refractory after 3 or more previous lines of chemotherapy (and/or HSCT) treatment
- AML or antecedent MDS secondary to prior chemotherapy
- Persistent clinically significant non-hematological toxicity that is Grade >1 by NCI CTCAE v4 from prior chemotherapy
- Patients who have had HSCT and are within 100 days of transplant and/or are still taking immunosuppressive drugs and/or have clinically significant graft-versus-host disease requiring treatment and/or have >Grade 1 persistent non hematological toxicity related to the transplant
- Clinically active central nervous system (CNS) leukemia. Patients with CNS leukemia, which is controlled, but who are still receiving IT therapy at study entry may be considered eligible and continue receive IT therapy at the discretion of the Investigator and with agreement of the Sponsor.
- Patients who have previously received AC220
- Disseminated intravascular coagulation (DIC) (diagnosis by laboratory or clinical assessment)
- Major surgery within 4 weeks prior to enrollment in the study
- Radiation therapy within 4 weeks prior to, or concurrent with study
- Use of concomitant drugs that prolong the time between the start of the Q wave and the end of the T wave (QT)/corrected interval between the Q wave and T wave (QTc) interval and/or are CYP3A4 inhibitors are prohibited with the exception of antibiotics, antifungals, and other antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the patient.
- Uncontrolled or significant cardiovascular disease
- Women who are pregnant, lactating, or unwilling to use contraception if of childbearing potential
- Men who are unwilling to use contraception if their partners are of childbearing potential
- Active, uncontrolled infection
- Human immunodeficiency virus positivity
- Active hepatitis B or C or other active liver disease
- History of cancer, except Stage 1 cervix or nonmelanotic skin cancer, with the possible exception of patients in complete remission
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00989261
Show 85 study locations
| Study Director: | Interim Chief Medical Officer | Ambit Biosciences Corporation |
| Responsible Party: | Daiichi Sankyo |
| ClinicalTrials.gov Identifier: | NCT00989261 |
| Other Study ID Numbers: |
AC220-002 2009-013093-41 ( EudraCT Number ) |
| First Posted: | October 5, 2009 Key Record Dates |
| Results First Posted: | November 29, 2019 |
| Last Update Posted: | December 11, 2019 |
| Last Verified: | December 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/ |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Clinical Study Report (CSR) |
| Time Frame: | Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication. |
| Access Criteria: | Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent. |
| URL: | https://vivli.org/ourmember/daiichi-sankyo/ |
|
AML AC220 acute FLT3 inhibitor kinase |
leukemia leukaemia myeloid relapsed refractory |
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute |
Neoplasms by Histologic Type Neoplasms Hematologic Diseases |